Aug 02, 2021 04:19 PM (GMT+8) · EqualOcean
After examination, the State Drug Administration approved the registration application of the innovative product "coronary CT flow reserve fraction calculation software" produced by Beijing Xinshiji Medical Technology Co., Ltd. The product can noninvasively evaluate the function of diseased blood vessels. It can not only evaluate the degree of stenosis of diseased blood vessels from the aspect of anatomical structure, but also reflect the degree of myocardial perfusion / ischemia in the current clinical situation from the aspect of hemodynamics, which improves the situation that the specificity of CCTA is not high.